ERBB2 and breast cancer: The considerable CNS activity of T-DXd was then confirmed in the TUXEDO-1 trial, a prospective, single-arm, phase 2 study recruiting patients with HER2-positive BC and untreated BMs or BMs progressing after previous local therapy, after previous exposure to trastuzumab and pertuzumab and with no indication for immediate local therapy.